Up to now, anti-PD-1/PD-L1 therapies have been recommended as first-line therapies for advanced or metastatic NSCLC with positive PD-L1 expressions and immunohistochemistry-detected PD-L1 expression is the only approved biomarker in the National Comprehensive Cancer Network guideline to select patients who are candidates for PD-1/PD-L1 inhibitors [11]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.